COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

被引：0
|
作者：
Vazquez, M. [1 ]
Canete, J. D. [2 ]
Nicolas, J. [3 ]
Peral, C. [4 ]
Gomez, S. [4 ]
Lopez, A. [4 ]
Prades, M. [5 ]
Rebollo, F. [4 ]
机构：
[1] Hosp Ramon & Cajal, Rheumatol Dept, Madrid, Spain
[2] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[3] Hosital Univ Mutua Terrassa, Pharm Dept, Terrassa, Spain
[4] Pfizer SLU, Madrid, Spain
[5] Outcomes10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY16
引用
收藏
页码：S904 / S904
页数：1
相关论文
共 50 条
  • [1] Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review
    Maese, Jesus
    Diaz del Campo, Petra
    Seoane-Mato, Daniel
    Guerra, Mercedes
    Canete, Juan D.
    REUMATOLOGIA CLINICA, 2018, 14 (02): : 81 - 89
  • [2] COST-EFFECTIVENESS OF BIOLOGICS COMPARED TO CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN FINLAND
    Joensuu, J. T.
    Aaltonen, K. J.
    Aronen, P.
    Sokka, T.
    Puolakka, K.
    Tuompo, R.
    Korpela, M.
    Vasala, M.
    Ilva, K.
    Nordstrom, D.
    Blom, M.
    VALUE IN HEALTH, 2015, 18 (07) : A648 - A648
  • [3] Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Patel, Aarat M.
    Lupash, Daniel
    Chew, Douglas
    Levesque, Marc C.
    Moreland, Larry W.
    CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (05) : 381 - 382
  • [4] Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Aarat M. Patel
    Daniel Lupash
    Douglas Chew
    Marc C. Levesque
    Larry W. Moreland
    Current Rheumatology Reports, 2011, 13 : 381 - 382
  • [5] Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
    Ha, So-Young
    Shim, Yoon-Bo
    Lee, Min-Young
    Koo, Bon-San
    Kim, Jae-Hoon
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Kim, Young-Joo
    Shin, Ju-Young
    Park, Mi-Hai
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 395 - 409
  • [6] Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
    So-Young Ha
    Yoon-Bo Shim
    Min-Young Lee
    Bon-San Koo
    Jae-Hoon Kim
    Ja-Young Jeon
    Hyun-Jeong Yoo
    Young-Joo Kim
    Ju-Young Shin
    Mi-Hai Park
    Rheumatology and Therapy, 2021, 8 : 395 - 409
  • [7] Predictors of effectiveness of biologic disease-modifying antirheumatic drugs (bDMARD) in the treatment of psoriatic arthritis
    Brandao, Natalia Dias
    Morgado, Marina
    Oliveira, Gerusa A.
    Acurcio, Francisco de Assis
    Guerra Junior, Augusto Afonso
    Alvares-Teodoro, Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 170 - 171
  • [8] Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review
    Kingsley, Gabrielle H.
    Scott, David L.
    PSORIASIS-TARGETS AND THERAPY, 2015, 5 : 71 - 81
  • [9] Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice
    Kuijper, T. Martijn
    Buisman, Leander R.
    Hazes, Johanna M.
    Weel, Angelique E.
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (07) : 965 - 967
  • [10] Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
    Ribeiro, Andre Lucas
    Abarza, Virginia Carrizo
    Gladman, Dafna
    Chandran, Vinod
    Eder, Lihi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4728 - 4730
12345